Literature DB >> 29374831

Use of procalcitonin in the diagnosis of tuberculosis in infants and preschool children.

Eneritz Velasco-Arnaiz1, Esther Pérez1, Desirée Henares2, Anna Fernández-López1, Anna Valls3, Pedro Brotons2,4, Clàudia Fortuny1,4,5,6, Antoni Noguera-Julian7,8,9,10.   

Abstract

Normal procalcitonin (PCT) levels have been reported in adult pulmonary tuberculosis (TB) but have not been previously investigated in children. We aimed to assess PCT levels at diagnosis of TB in young children in a low-burden setting. In a cross-sectional observational study in a referral pediatric center in Barcelona (Spain), we assessed the value of PCT and other inflammatory markers (leucocyte counts, C-reactive protein, and erythrocyte sedimentation rate) in the diagnosis of TB in pre-school children (< 6 years at diagnosis, n = 45), as compared with two control groups (pneumococcal pneumonia, n = 25; and healthy controls, n = 49). Normal PCT levels were observed at diagnosis of TB in most cases, while C-reactive protein values and leucocyte counts were slightly elevated when compared to healthy controls. All three inflammatory biomarkers were significantly higher in children with pneumococcal pneumonia.
CONCLUSIONS: In our study, PCT was not a useful diagnostic test for TB in young children. In a low-burden TB setting, PCT may be of some value in distinguishing pulmonary TB from pneumococcal pneumonia. What is Known: • Diagnosis of pediatric tuberculosis on clinical evidence is difficult, particularly in infants and small children. • Studies in adults with tuberculosis have mostly reported normal procalcitonin levels at diagnosis. What is New: • In pre-scholars with tuberculosis, erythrocyte sedimentation rate and white blood cell counts were higher than in healthy controls, but procalcitonin was not. • Procalcitonin may be useful in the differential diagnosis of intrathoracic tuberculosis and pneumococcal pneumonia.

Entities:  

Keywords:  C-reactive protein; Erythrocyte sedimentation rate; Pneumonia; Procalcitonin; Tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 29374831     DOI: 10.1007/s00431-018-3099-9

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Usefulness of serum procalcitonin levels in pulmonary tuberculosis.

Authors:  M Ugajin; S Miwa; M Shirai; H Ohba; T Eifuku; H Nakamura; T Suda; H Hayakawa; K Chida
Journal:  Eur Respir J       Date:  2010-06-07       Impact factor: 16.671

Review 2.  Procalcitonin and community-acquired pneumonia (CAP) in children.

Authors:  Bivona Giulia; Agnello Luisa; Scazzone Concetta; Lo Sasso Bruna; Bellia Chiara; Ciaccio Marcello
Journal:  Clin Chim Acta       Date:  2015-10-03       Impact factor: 3.786

Review 3.  A proposed comprehensive classification of tuberculosis disease severity in children.

Authors:  Catherine A Wiseman; Robert P Gie; Jeffrey R Starke; H Simon Schaaf; Peter R Donald; Mark F Cotton; Anneke C Hesseling
Journal:  Pediatr Infect Dis J       Date:  2012-04       Impact factor: 2.129

Review 4.  Tuberculosis as a cause or comorbidity of childhood pneumonia in tuberculosis-endemic areas: a systematic review.

Authors:  Jacquie N Oliwa; Jamlick M Karumbi; Ben J Marais; Shabir A Madhi; Stephen M Graham
Journal:  Lancet Respir Med       Date:  2015-01-29       Impact factor: 30.700

Review 5.  Procalcitonin.

Authors:  Julie Davies
Journal:  J Clin Pathol       Date:  2015-06-29       Impact factor: 3.411

6.  Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.

Authors:  Stephen M Graham; Tahmeed Ahmed; Farhana Amanullah; Renee Browning; Vicky Cardenas; Martina Casenghi; Luis E Cuevas; Marianne Gale; Robert P Gie; Malgosia Grzemska; Ed Handelsman; Mark Hatherill; Anneke C Hesseling; Patrick Jean-Philippe; Beate Kampmann; Sushil Kumar Kabra; Christian Lienhardt; Jennifer Lighter-Fisher; Shabir Madhi; Mamodikoe Makhene; Ben J Marais; David F McNeeley; Heather Menzies; Charles Mitchell; Surbhi Modi; Lynne Mofenson; Philippa Musoke; Sharon Nachman; Clydette Powell; Mona Rigaud; Vanessa Rouzier; Jeffrey R Starke; Soumya Swaminathan; Claire Wingfield
Journal:  J Infect Dis       Date:  2012-03-22       Impact factor: 5.226

Review 7.  Value of procalcitonin in differentiating pulmonary tuberculosis from other pulmonary infections: a meta-analysis.

Authors:  S-L Huang; H-C Lee; C-W Yu; H-C Chen; C-C Wang; J-Y Wu; C-C Lee
Journal:  Int J Tuberc Lung Dis       Date:  2014-04       Impact factor: 2.373

8.  Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP.

Authors:  K Nyamande; U G Lalloo
Journal:  Int J Tuberc Lung Dis       Date:  2006-05       Impact factor: 2.373

9.  Procalcitonin and C-reactive protein for invasive bacterial pneumonia diagnosis among children in Mozambique, a malaria-endemic area.

Authors:  Núria Díez-Padrisa; Quique Bassat; Sonia Machevo; Llorenç Quintó; Luis Morais; Tacilta Nhampossa; Cristina O'Callaghan-Gordo; Antoni Torres; Pedro L Alonso; Anna Roca
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

Review 10.  Use of procalcitonin for the prediction and treatment of acute bacterial infection in children.

Authors:  Richard Pierce; Michael T Bigham; John S Giuliano
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

View more
  1 in total

Review 1.  Tuberculosis in childhood and adolescence: a view from different perspectives.

Authors:  Tony T Tahan; Betina M A Gabardo; Andrea M O Rossoni
Journal:  J Pediatr (Rio J)       Date:  2019-12-18       Impact factor: 2.990

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.